Novavax's Covid-19 vaccine shows long-term efficacy in UK trial

The protein-based vaccine continued to provide protection and maintained overall efficacy of 82.7% over a six-month period.

The Straits Times | I+D | Farmacia |

Leer noticia completa en el medio original
Spanish